Analysis of genomic abnormalities in CLL, DLBCL-RS, and de novo DLBCL demonstrated that cell cycle deregulation via inactivation of TP53 and CDKN2A is a main driver of the transformation from CLL to aggressive lymphoma [30]. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.